메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

전체기사

AI Platform to Combat Muscle Loss and Preserve Metabolic Vitality for GLP-1 Users

Livelively USA combines AI insights with Eastern wellness principles to support healthier long-term weight management behaviors. NEW YORK, Dec. 22, 2025 -- Weight-loss medications are reshaping global healthcare, with the anti-obesity drug market projected to approach $100 billion by 2030, according to Goldman Sachs. As millions begin GLP-1 therapy, interest is growing around how to maintain strength, vitality, and well-being throughout treatment. Livelively USA Inc. today introduced a metabolic wellness platform that integrates predictive AI with Integrative Longevity S
- 김갑성 기자
- 2025-12-22 21:00
Kazia Therapeutics Regains Full Nasdaq Listing Compliance

[ 메디채널 황정호 기자 ] Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY, Dec. 22, 2025 -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA), a clinical-stage oncology company focused on developing innovative therapies for cancer, today announced that it has regained full compliance with all applicable listing standards of Nasdaq. On December 18, 2025, the Company received written notification from Nasdaq confirming that Kazia has regained compliance with Nasdaq Listing Rule
- 황정호 기자
- 2025-12-22 21:00
SenseTime Launches Seko 2.0 Drama Series Generation Platform

Powered by LightX2V inference framework to enable low‑cost, high-throughput video generation HONG KONG, Dec. 22, 2025 -- SenseTime launched its Seko 2.0, a multi-episode drama generation agent tailored for short drama and motion comic creators. Supporting production up to 100-episode series, Seko 2.0 ensures consistency in characters, scenes, and props across episodes. It significantly boosts production efficiency, reducing comic drama production time by 80% to 90% compared to traditional methods. Seko 2.0 is powered by SenseTime's open‑source LightX2V framework, the in
- 김장윤(JASON KIM) 기자
- 2025-12-22 18:30
Robert De NiroがSalboyと共にマンチェスターを訪問する中、Nobu Manchesterが着工式を実施

マンチェスター（英国）, 2025年12月22日 -- Robert De Niroは、Nobu Hospitalityの共同創業者であるシェフのNobu MatsuhisaとMeir Teperと共にマンチェスターを訪問し、Salboyの現場に合流してNobu Manchesterの起工式とプロジェクトの次の段階の開始を祝いました。 Nobu Manchester Groundbreaking Event Highlights - Robert De Niro visited Manchester with fellow Nobu Hospitality founders Chef Nobu Matsuhisa and Meir Teper, joining Salboy on site to mark the Nobu Manchester groundbreaking and the next stage of the project’s delivery. 式典はNobu Hospitalityの創業者（Robert De Niro、シェフNobu Matsuhisa、Meir Teper）とSalboyの共同創業者（Fred Done、Simon Ismail）が主催しまし
- 김장윤(JASON KIM) 기자
- 2025-12-22 17:52
Yii Partners with Japan's ANDS Corporation: Building Skin Resilience through Pharmaceutical-Grade Science

HONG KONG, Dec. 22, 2025 -- Japanese skincare brand Yii is collaborating with ANDS Corporation (hereinafter "ANDS"), an affiliate of Rohto Pharmaceutical Co., Ltd., to explore the niche skincare market with pharmaceutical-grade scientific excellence. The collaboration combines over 60 years of ANDS's formulation expertise with Yii's Eastern philosophy of "Nourish effortless beauty," delivering proven efficacy and high safety for sensitive, barrier-compromised, and early-aging skin types. Where Eastern Philosophy Meets Japanese Craftsmanship Modern lifestyles,
- 김갑성 기자
- 2025-12-22 17:51
Mirae Asset's Global ETF Platform Surpasses $200 Billion In AUM, Marking a New Growth Milestone

[ 메디채널 황정호 기자 ] Firm's ETF assets have doubled in recent years, reflecting its innovative ETF leadership and multi-year global expansion strategy HONG KONG, Dec. 22, 2025 -- Mirae Asset Global Investments ("Mirae Asset") announced that assets under management across its global exchange traded fund (ETF) platform have surpassed $200 billion[1], marking a significant milestone in the firm's ongoing global expansion. The achievement underscores the accelerating growth of Mirae Asset's ETF business and its emergence as one of the industry's most comprehensive and innovative ETF
- 황정호 기자
- 2025-12-22 17:02
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype

The secondary analysis of the PACE trial highlights the value of counting Circulating Tumor Cells (CTCs) in the blood to help guide treatment escalation or de-escalation in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer whose disease progressed after treatment with aromatase inhibitors plus CDK4/6 inhibitors. CTC count is a standalone predictive biomarker, independent of clinical risk factors and circulating tumor DNA. BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., Dec. 22, 2025 -- Menarini Silicon Biosystems, a pioneer of cell-based l
- 김갑성 기자
- 2025-12-22 16:00
Beko Secures €100 Million Sustainability-Linked Loan from IFC to Drive Global Innovation and Net-Zero Transformation

Beko has secured its first sustainability-linked loan to expand renewable energy capacity, strengthen earthquake resilience, and promote next-generation eco-efficient appliances and diversity, with sustainability targets tied to emission reduction and increased women's representation. ISTANBUL, Dec. 22, 2025 -- Beko, the leading global home appliance company, has signed a €100 million sustainability-linked loan with IFC, a member of the World Bank Group. Marking Beko's first sustainability-linked loan, the agreement reinforces the company's commitment to integrating sustainabil
- 황정호 기자
- 2025-12-22 16:00
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy

[ 메디채널 김갑성 기자 ] Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 -- Guardant Health Japan Corp. today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Guardant360® CDx on 23 October 2025 as a companion diagnostic to identify ESR1 mutations in patients with hormone receptor–positive, HER2-negative breast cancer with disease progression following endocrine therapy, for consi
- 김갑성 기자
- 2025-12-22 16:00
ベコ、IFCから1億ユーロのサステナビリティ連動型融資を獲得し、グローバルなイノベーションとネットゼロ変革を推進

[ 메디채널 황정호 기자 ] ベコは、再生可能エネルギー容量の拡大、地震耐性の強化、次世代の環境効率の高い機器や多様性の促進を目的とした初の持続可能性連動融資を確保し、持続可能性目標を排出量削減と女性の代表権拡大に結び付けている。イスタンブール, 2025年12月22日 -- 世界有数の家電メーカーであるBekoは、世界銀行グループの一員であるIFCと1億ユーロの持続可能性連動融資契約を締結しました。この契約はベコにとって初の持続可能性関連融資となり、バリューチェーン全体に持続可能性を統合し、エネルギー効率の高い技術の革新を推進するという同社の取り組みを強化するものとなる。 IFC は新興市場の民間セクターに重点を置く世界最大の開発機関です。新たに確保した資金により、再生可能エネルギー利用に特化したベコ社の2つの太陽光発電所の継続的な運営が促進され、6つの生産施設が強化され、潜在的な地震被害に対する耐性が向上する。この融資により、ベコの世界的な研究開発（R&D）も加速し、デジタル化と、スマートで資源効率が高く健康を重視した家電製品の開発が促進され、世界中で持続可能な暮らしがサポートされることになる。この5年間の融資は、同社の持続可能性連動融資枠組みに基づいて構成されており、温室効果ガス排出量の削減と従業員
- 황정호 기자
- 2025-12-22 16:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-01-11_SUN

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 11일 14시 40분